Measuring Cortisol Levels in Persons With Parkinson's (PD)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02727270

Acronym

CORT-PD

Enrollment

131

Registered

2016-04-04

Start date

2016-06-30

Completion date

2023-11-16

Last updated

2023-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Huntington Disease, Parkinson Disease

Keywords

Movement disorders, Metabolic Stress, Basal Ganglia Disorders

Brief summary

The objective of this study is to evaluate the cortisol awakening response with persons with Parkinsons Disease (PD), Huntingtons Disease (HD), and controls. These data are desired so experience can be gained with measuring stress levels subjectively and objectively in persons with PD, HD, and controls.

Detailed description

Telephone consent will be obtained. Participants will collect saliva at twelve time points - four times a day for three days. Visits will be conducted virtually (over the internet). The virtual visit is to assess Parkinson's or Huntington's disease status, stress, mood, and quality of life.

Interventions

OTHERNo Intervention - Observational Study

No Intervention - Observational Study

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Yes

Inclusion criteria

Group (3) Inclusion: * No significant neurological disorder * PSS score of greater than or equal to 13. Group (5) Inclusion: * HD diagnosis or HD gene carrier * a Perceived Stress Scale (PSS) score higher than or equal to 13. Group (6) Inclusion: * HD diagnosis or HD gene carrier * PSS score lower than 13 Group (7) Inclusion: * PD diagnosis * Prior completion of the study.

Exclusion criteria

* The use of medications known to effect cortisol levels (estrogen, synthetic glucocorticoids, androgens, phenytoin, spironolactone, prednisone, prednisolone, and hydrocortisone).

Design outcomes

Primary

Measure	Time frame	Description
Awakening Salivary Cortisol level (ug/dL) Response	Collected upon awakening and 30 minutes after awakening	Salivary Cortisol level (ug/dL) Response is the change in cortisol between awakening and 30 minutes after awakening.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026